---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038033"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:11:17.230875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MindMed Q2 net loss $29.1M, cash $116.9M; MM-120 GAD topline readout on track for Q4 2023

## Summary
- Net loss of $29.1M in Q2 2023 vs $17.0M in Q2 2022; R&D spend rose to $14.8M ($9.3M prior).
- Cash and equivalents $116.9M at June 30, 2023, funding operations into first half of 2025.
- MM-120 Phase 2b for GAD enrollment target lowered to 180 patients; topline results expected Q4 2023.
- MM-120 Phase 2a for ADHD over 80% enrolled; topline readout expected Q4 2023 / Q1 2024.
- Exclusive license agreement with Catalent for Zydis ODT formulation of MM-120 for pivotal trials.

## SEC filing metadata
- accession: 0000950170-23-038033
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/0000950170-23-038033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/mnmd-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038033
- JSON: https://secwatch.observer/filing/0000950170-23-038033.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038033.txt

## Key facts
- Earnings Releases
  Definium Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release (the "Press Release:) announcing its financial results for its fiscal quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/0000950170-23-038033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.